**Appendix Table E59. Results from studies assessing the ability of VASP to predict platelet reactivity during followup (when used as a continuous measurement) in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year**  **UID**  **Country**  **Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Reactivity Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **No. with given phenotype** | **Platelet reactivity measurement for the phenotype group**  **[metric]** | **SD/SE (report value and metric)** | **Statistical method** | **Mean difference (state if other metric)** | **95% CI of mean difference (state if other metric)** | **P (between which groups?)**  **[statistical test]** | **Adjusted?**  **[YES/NO/NR]**  **If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Kalantzi, 2011{Kalantzi, 2011 19 /id}  21255245  Greece  NR | Clopidogrel 300 mg loading & 75 mg/d | VASP at Day 5 | Percent inhibition of maximumplatelet aggregation (IPA,%) | Light transmittance aggregometry in platelet-rich plasm using 2.5 μM ADP & IPA achieved within 3 min | 30 days | Nonresponder | 15 | 51.8% | NR | NR | NR | NR | NR | NR | NR | Value obtained from digitizing Fig1l One P value of 0.01 is reported between IPA values of 30 days vs 5 days but not specified for which ADP conc |
|  |  |  |  |  | 30 days | Responder | 46 | 56.2% | NR | NR | NR | NR | NR | NR | NR |  |
|  |  |  | Percent inhibition of maximumplatelet aggregation (IPA,%) | Light transmittance aggregometry in platelet-rich plasm using 5 μM ADP & IPA achieved within 3 min | 30 days | Nonresponder | 15 | 40.9% | NR | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  | 30 days | Responder | 46 | 50.6% | NR | NR | NR | NR | NR | NR | NR |  |
|  |  |  | Percent inhibition of maximumplatelet aggregation (IPA,%) | Light transmittance aggregometry in platelet-rich plasm using 10 μM ADP & IPA achieved within 3 min | 30 days | Nonresponder | 15 | 30.4% | NR | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  | 30 days | Responder | 46 | 35.5% | NR | NR | NR | NR | NR | NR | NR |  |
|  |  |  | P-selectin expression (% positive cells) | Flow cytometry, using anti-CD62P-PE after activation with 100 μM of ADP (10 min, in static conditions at 37 oC) | 30 days | Nonresponder who underwent PCI | 8 | Median= 29 | Range= 24,35 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  | 30 days | Nonresponder who underwent conservative treatment | 7 | Median= 27 | Range= 22,32 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  | 30 days | Responder | 46 | Median= 27 | Range= 24,34 | NR | NR | NR | NR | NR | NR |  |
|  |  |  | Platelet/monocyte conjugates (% positive particles) | Flow cytometry, using anti-CD61-PerCP and anti-CD14-FITC after activation with 100 μM of ADP (10 min, in static conditions at 37 oC) | 30 days | Nonresponder who underwent PCI | 8 | Median= 49 | Range= 42,57 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  | 30 days | Nonresponder who underwent conservative treatment | 7 | Median= 51 | Range= 45,60 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  | 30 days | Responder | 46 | Median= 44 | Range= 37,49 | NR | NR | NR | NR | NR | NR |  |
|  |  |  | Platelet/neutrophil conjugates (% positive particles) | Flow cytometry, using anti-CD41a-FITC and anti-CD45-PE after activation with 100 μM of ADP (10 min, in static conditions at 37 oC) | 30 days | Nonresponder who underwent PCI | 8 | Median= 25 | Range= 21,32 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  | 30 days | Nonresponder who underwent conservative treatment | 7 | Median= 26 | Range= 21,32 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  | 30 days | Responder | 46 | Median= 23 | Range= 17,28 | NR | NR | NR | NR | NR | NR |  |
| Tselepis, 2011 {Tselepis, 2011 1 /id}  22008470  Greece  NR | aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day. | VASP | VASP-ADP  PRI | VASP-ADP | 30 days | non-responder | 17 | mean 41.2 | SD 16.1 | NR | NR | NR | <0.01  comparing with 5 days values  t-test | NR | NR |  |
|  |  |  |  |  |  | responder | NR | NR | NR | NR | NR | NR | NR | NR | NR |  |
| Tselepis, 2011 {Tselepis, 2011 1 /id}  22008470  Greece  NR | aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day. | VASP | LTA-ADP 5uM | platelet aggregation | 30 days | responder | 57 | 5uMADP  mean36 | 13 | NR | NR | NR | <0.001comparing with baseline values  t-test | NR | NR |  |
|  |  |  |  |  |  | non-responder | 17 | 5uM ADP mean 40 | 14 |  |  |  | <0.001 comparing with baseline values  <0.01 comparing with 5 days results  t-test |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Tselepis, 2011 {Tselepis, 2011 1 /id}22008470Greece  NR | aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day. | VASP | LTA-ADP 10uM | platelet aggregation | 30 days | responder | 57 | 10uM ADP  mean 52 | 11 | NR | NR | NR | <0.001  comparing with baseline values  t-test | NR | NR |  |
|  |  |  |  |  |  | non-responder | 17 | 10uM ADP mean 55 | 10 |  |  |  | <0.001comparing with baseline values  <0.01 comparing with 5 days results  t-test |  |  |  |
| Tselepis, 2011 {Tselepis, 2011 1 /id}  22008470  Greece  NR | aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day. | VASP | LTA- TRAP | platelet aggregation | 30 days | responder | 57 | trap 10uM mean 61 | 15 | NR | NR | NR | <0.001  comparing with baseline values  t-test | NR | NR |  |
|  |  |  |  |  |  | non-responder | 17 | trap 10uM mean 60 | 9 |  |  |  | <0.001  comparing with baseline values  t-test |  |  |  |
| Tselepis, 2011 {Tselepis, 2011 1 /id}  22008470  Greece  NR | aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day. | VASP | p-selection expression (MFI) | p-selection expression (MFI) | 30 days | responder | 57 | mean 26 | SD 10 | NR | NR | NR | <0.001  comparing with baseline values  t-test | NR | NR |  |
|  |  |  |  |  |  | non-responder | 17 | mean 23 | SD 8 |  |  |  | <0.001  comparing with baseline values  t-test |  |  |  |
| Tselepis, 2011 {Tselepis, 2011 1 /id}  22008470  Greece  NR | aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day. | VASP | platelet/monocyte conjugates | platelet/monocyte conjugates  (% positive particles) | 30 days | responder | 57 | mean 40 | SD 10 | NR | NR | NR | <0.001  comparing with baseline values  t-test | NR | NR |  |
|  |  |  |  |  |  | non-responder | 17 | mean 44 | SD 12 |  |  |  | <0.001  comparing with baseline values  t-test |  |  |  |
| Tselepis, 2011 {Tselepis, 2011 1 /id}  22008470  Greece  NR | aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day. | VASP | platelet/monocyte conjugates | platelet/neutrophil conjugates (% positive particles) | 30 days | responder | 57 | mean 22 | SD 9 | NR | NR | NR | <0.001  comparing with baseline values  t-test | NR | NR |  |
|  |  |  |  |  |  | non-responder | 17 | mean 27 | SD 10 |  |  |  | <0.001  comparing with baseline values  t-test |  |  |  |